0001493152-26-022950
SEC filingMixed Q1 with flat revenue and widening losses, as grant revenue ended and R&D spending fell, while cash burn improved but liquidity remains tight.
Provectus reported revenue of $278.6K for Q1 2026, unchanged from the prior year period. However, this stability masks a significant shift: the prior year's revenue was entirely grant-based, and that grant program has now concluded, leaving the company with no recurring revenue source. Operating income worsened to -$1.2M from -$1.1M, a 13.7% decline, as the loss of grant revenue was only partially offset by lower research and development expenses. The decrease in R&D costs was driven by reduced clinical trial and research-related activities, including manufacturing and development work associated with a new drug candidate, as well as lower payroll-related expenses and insurance costs. Net income also deteriorated to -$1.3M from -$1.1M, a 13.2% decline, reflecting the same dynamics.
Despite the widening net loss, net cash used in operating activities improved significantly to -$357.6K from -$1.1M in the prior year period. This improvement was driven by working capital changes and a lower net loss, though the company continues to generate negative cash flows from operations. Management has acknowledged the need for additional capital and plans to access resources through possible public or private equity offerings, debt offerings (including the 2025 unsecured convertible notes), exchange offers, corporate collaborations, or other means. However, there can be no assurance that these efforts will be successful. The company's ability to continue as a going concern is dependent on securing such financing.
Provectus continues to advance its small molecule platform based on pharmaceutical-grade rose bengal (RBS), with clinical development programs in oncology (intratumoral PV-10 for melanoma, liver cancers, and breast cancer), dermatology (topical PH-10 for psoriasis and atopic dermatitis), and ophthalmology (PV-305 for infectious keratitis). The company also has proof-of-concept programs in oral formulations for solid tumors and hematology, wound healing, and animal health. Management expects R&D expenses to increase in the future as the company advances its existing product candidates through clinical trials and pursues regulatory approval. The company's ability to execute on its business plan is contingent on securing additional financing. The primary business objective is to build the company into a commercial-stage biotechnology company, but success is uncertain. Investors should monitor the company's ability to raise capital through the 2025 Financing or other means, as well as progress in clinical trials and potential co-development collaborations.